• Educational resources
  • Events
  • Expert Panel
  • Learning Hub
    Learning Hub
    • EoE Learning Hub
    • COPD Learning Hub
    • Rhinology Learning Hub
    • Type 2 Asthma Learning Hub
    • Prurigo Nodularis Learning Hub
    • Atopic Dermatitis Learning Hub
No matches
  • Cookie policy
  • Privacy policy
  • About us
  • Join ADVENT
  • Contact us

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2026 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 - 4.0 - 10/2025

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: Czech RepublicChange country/region

Educational Resources

Categories
Dermatology: 
  • Atopic dermatitis
  • Prurigo nodularis
Gastroenterology: 
  • Eosinophilic esophagitis
Pulmonology: 
  • Asthma
  • Chronic obstructive pulmonary disease
Rhinology: 
  • Chronic rhinosinusitis with nasal polyps
Filters
Topic: 
  • Burden of disease
  • Pathophysiology
  • Guidelines and recommendations
  • Clinical management
  • Co-existing type 2 inflammatory diseases
Format: 
  • Expert Video
  • Podcast
  • Slide presentation
  • Infographic
  • Video animation
  • Interactivity
Length: 
  • Short (<5 minutes)
  • Medium (5-15 minutes)
  • Long (> 15 minutes)
Sort by: Newest
  • Newest
  • Oldest
  • A-Z
  • Z-A
Early Intervention May Have the Potential to Alter the Trajectory of Atopic Dermatitis
Dermatology
2 min
expert video

Early Intervention May Have the Potential to Alter the Trajectory of Atopic Dermatitis

Unpacking the Significant Burdens of Atopic Dermatitis
Dermatology
2 min
expert video

Unpacking the Significant Burdens of Atopic Dermatitis

Prurigo Nodularis Management Goals: From Itch Control to Improved Quality of Life
Dermatology
2 min
expert video

Prurigo Nodularis Management Goals: From Itch Control to Improved Quality of Life

Patients With Prurigo Nodularis Have a High Prevalence of Atopic and Non-Atopic Comorbidities​
Dermatology
2 min
expert video

Patients With Prurigo Nodularis Have a High Prevalence of Atopic and Non-Atopic Comorbidities​

Prurigo Nodularis Is a Challenging Diagnosis
Dermatology
2 min
expert video

Prurigo Nodularis Is a Challenging Diagnosis

Type 2 Inflammation Is a Driving Factor for Atopic Dermatitis and Related Comorbidities
Dermatology
2 min
expert video

Type 2 Inflammation Is a Driving Factor for Atopic Dermatitis and Related Comorbidities

Neuroimmune Dysfunction Is Critical in the Pathophysiology of Prurigo Nodularis
Dermatology
2 min
expert video

Neuroimmune Dysfunction Is Critical in the Pathophysiology of Prurigo Nodularis

Pathways Driving Chronic Airway Remodeling in Asthma
Pulmonology
4 min
videoanimation

Pathways Driving Chronic Airway Remodeling in Asthma

Importance of Monitoring and Maintenance in EoE
Gastroenterology
5 min
Infographic

Importance of Monitoring and Maintenance in EoE

    1234
    ...
    18